Smoking cessation requires a structured clinical approach that prioritizes brief, actionable advice and the establishment of a firm quit date to transition patients into the preparation stage. Evidence-based pharmacotherapy remains the cornerstone of success, specifically the "basal-bolus" strategy of combining long-acting nicotine patches with short-acting therapies like mini-lozenges or gum, which triples quit rates. Varenicline stands out as the most effective non-nicotine option, with clinical data confirming its safety profile even for patients with psychiatric histories. While e-cigarettes show potential in helping some smokers transition away from combustible tobacco, they carry risks of dual use and long-term dependence; therefore, they should serve as a secondary option with a defined off-ramp. Addressing past triggers and celebrating prior successes further bolsters patient confidence and long-term abstinence.
Sign in to continue reading, translating and more.
Open full episode in Podwise